Fluoropyrimidines: A critical evaluation

Oncology

Volumn 57, Issue SUPPL. 1, 1999, Pages 2-8

  Brito, Rogelio A ^a   Medgyesy, Diana ^a   Zukowski, Thomas H ^a   Royce, Melanie E ^a   Ravandi Kashani, Farhad ^a   Hoff, Paulo M ^a   Pazdur, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 FU; Colon cancer; Emitefur; Eniluracil; Fluoropyrimidines; Oral chemotherapy; S 1; UFT; Xeloda (capecitabine)

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; ALPHA INTERFERON; ANTHRACYCLINE; BMS 247616; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; EMITEFUR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; ORZEL; PACLITAXEL; TEGAFUR; TRIMETREXATE; UFT; UNCLASSIFIED DRUG;

ANOREXIA; ASTHENIA; BONE MARROW SUPPRESSION; BREAST METASTASIS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG TOXICITY; DRUG TUMOR LEVEL; DYSPNEA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; STOMATITIS; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; LEUCOVORIN; OXONIC ACID; PYRIDINES; TEGAFUR; URACIL;

EID: 0032771857     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055262     Document Type: Review

References (52)

1. Heidelberger C, Chandler NK, Douglas H Jr: Fluorouracil pyrimidine. A new class of tumor inhibiting compounds. Nature 1957;179:633-666.
2. Allegra CJ, Grem JL: Antimetabolites in Cancer, Principles and Practice of Oncology, 5th ed. De Vita VT, Hellman S, Rosenberg SA (eds). Philadelphia, Lippincott-Rosen, 1997, pp 432-452.
3. Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H Jr, Cornell G: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil - a preliminary report. Cancer 1977;39:34-40.
4. Lokich J, Ablgren J, Guillo J, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal cancer: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-432.
5. The Meta-analysis Group in Cancer: Efficacy of intravenous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308.
6. Hansen R, Quebberman E, Andeno T: 5-Fluorouracil by protracted venous infusion. Oncology 1989;46:245-250.
7. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40:2223-2228.
8. Advanced Colorectal Meta-Analysis Project: Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
9. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailiard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20.
10. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A: Phase II study of fluorouracil (5-FU) and its modulation in advanced colorectal cancer: A Southwest Oncology Group (SWOG) Study. J Clin Oncol 1995;13:1303-1311.
11. De Gramont A, Bosset JF, Milan C, Rougier P, Boucher O, Etienne P-E, Morvan F, Louvet C, Guillot T, François E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 1997;15:803-815.
12. Wadler S, Schwartz E, Goldman M, Lyver A, Rader M, Zimmerman M, Itri I, Weinberg V, Wiernik PH: Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-1775.
13. Pazdur R, Abbruzzese J, Faintuch J, Ajani J, Patt Y, Jackson D, Markowitz A, Winn R, Gutterman J, Levin B: Phase II study of recombinant interferon alpha and 5-fluorouracil in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1990;9:117 (abstract 455).
14. Kemeny N, Younes A, Secter K, Kelsen D, Sammarco P, Adams L, Derby S, Murray P, Houston C: Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 1990; 66:2470-2475.
15. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M: Royal Marsden Phase III trial of fluorouracil with or without interferon alpha-2b in advanced colorectal cancer. J Clin Oncol 1995;13:1297-1303.
16. Romanini A, Li WW, Colafiore JR, Bertino JR: Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil but not methotrexate/fluorouracil in CCRF-CEM cells. J Natl Cancer Inst 1992;84:1033-1038.
17. Conti JA, Kemeny N, Seiter K, Goker E, Tong W, Andre M, Ragusa K, Bertino JR: Trial of sequential trimetrexate, fluorouracil and high dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994;12:695-700.
18. Coates A, Abraham S, Kaye S, Sowerbutts T, Frewin C, Fox RM, Tattersall MH: On the receiving end - patients perceptions of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-208.
19. Claessen K, de Vries J, Huissman S, Dubbelman R, Van Rheenen CM, Van Dam FS, de Graaf PW: Long-term venous access with a Hickman catheter, complications and patient satisfaction. Neth J Surg 1990;42:47-49.
20. Hoff PM, Pazdur R, Benner SE, Canetta R: UFT and leucovorin: A review of its clinical development and therapeutic potential in the oral treatment of cancer. Anti Cancer Drugs 1998;9:479-490.
21. Liu G, Franssen E, Fitch M, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
22. Taguchi T: Experience with UFT in Japan. Oncology 1997;11:30-34.
23. Shirasaka T, Fujita F, Fujita M, Fukushima M, Taguchi T, Fujii S: Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice. Gan To Kagaku Ryoho 1990;17: 1871-1876.
24. Cao S, Rustum Y, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-FU efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54: 1507-1510.
25. Liu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53: 5433-5438.
26. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-690.
27. Miwa M, Ura M, Nishida N, Sawada T, Ishikawa T, Mari K, Shimma N, Umeda I, Isitsuka H: Design of a novel fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
28. Cao S, Lu K, Ishitsuka H, Rustum YM: Antitumor activity of capecitabine against fluorouracil sensitive and resistant tumors. Proc Am Soc Clin Oncol 1997;16:226a (abstract 795).
29. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998;16:1795-1802.
30. Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, Osterwalder B, Van Oosterom AT: A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumours. Clin Cancer Res 1998;4:2755-2761.
31. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16:2977-2985.
32. Schuller J, Cassidy J, Reigner B, Pietrzak C, Roos B, Springer H, Ishitsuka H, Utoh M, Dumont E: Tumor selective activation of capecitabine in colorectal cancer patients. Onkologie 1997;20:suppl 1 (abstract A732).
33. Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, Osterwalder B, Dalley D, Pazdur R, Verweij J: A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancers. Proc Am Soc Clin Oncol 1997;16:227a (abstract 798).
34. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II studies. Cancer Chemother Pharmacol 1988;22:333-338.
35. Pazdur R, Lassere Y, Diaz-Canton E, Ho DH: Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. Cancer Invest 1998;161:145-151.
36. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready Bl: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12:2296-2300.
37. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP: A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin: An active oral regimen for advanced colorectal cancer. Cancer 1995;75:782-785.
38. Gonzalez-Baron M, Feliu J, de la Gandara I, Espinosa E, Colmenarejo A, Martinez B, Blanco E, Garcia-Giron C, Juarez F, Garrido P: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer: A phase II study. Eur J Cancer 1995;31:2215-2219.
39. Shirasaka T, Shimamato Y, Ohsimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytoxicity of 5-fluorouracil by two biochemical modulators. Anti-cancer Drugs 1996;7:548-557.
40. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-4009.
41. Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito M: The oral fluorouracil prodrugs. Oncology (Huntingt) 1998;12:48-51.
42. Peters GJ, Van Groeningen CJ, Schomage JH, Gall HE, Noordhuis P, de Vries M, Van Kullenburg A, Hanauske A-R: Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5FU)-based antineoplastic agent: Proc Am Soc Clin Oncol 1997;16:227a (abstract 800).
43. Ohtsu A, Sakata Y, Horikoshi N, Mitachi Y, Sugimachi T, Taguchi T: Phase II study of S-1 patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1998;17:262a (abstract 1005).
44. Horikoshi N, Mitachi Y, Sakata Y, Sugimachi K, Taguchi T: S-1, new oral fluoropyrimidine, is very active in patients with advanced gastric cancer (early phase II study). Proc Am Soc Clin Oncol 1996;15:206 (abstract 466).
45. Taguchi T, Horikoshi N, Kinoshita H, Toge T, Takashima S: Early phase II study of S-1 in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1996;15:121 (abstract 151).
46. Fujii M, Kanzaki J, Satake B, Baba S, Inuyama Y: Early phase II study of S-1 in patients with advanced head and neck cancer. Proc Am Soc Clin Oncol 1996:15:316 (abstract 894).
47. Baba H, Ohtsu A, Sakata Y, Mitachi Y, Sugimachi K, Taguchi T: Late phase II study of S-1 in patients with advanced colorectal cancer in Japan. Proc Am Soc Clin Oncol 1998;17:277a (abstract 1065).
48. Sasaki T: New anti-cancer drugs for gastrointestinal cancers. Gan To Kagaku Ryoho 1997; 24:1925-1931.
49. Porter D, Chestnut W, Merril B, Spector T: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992;267:5236-5242.
50. Baker S, Khor S, Adjej A, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorious SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetics, oral bioavailability and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996;14: 3085-3096.
51. Baccanari D, Davis S, Knick V, Spector T: 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-FU. Proc Natl Acad Sci USA 1993;90: 11064-11068.
52. Mani S, Beck T, Chevlen E, et al: A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998;17:281A.